A Phase 1 interventional study of AZP-531 and Placebo in Type 2 Diabetes Mellitus, sponsored by Alizé Pharma. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-18.
Sponsored by Alizé Pharma · Phase 1, Interventional, and Treatment
Objectives:
Primary Objectives
Secondary Objectives • To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses.
Exploratory Objectives
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 108 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →This is the only study on the registry with Alizé Pharma as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
subcut administration once or twice daily
Drug: AZP-531
subcut administration once or twice daily
Drug: Placebo
To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.
Time frame: 1 to 14 days
To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses
Time frame: 1 to 14 days
To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers
Time frame: 1 to 14 days
This study is status unknown, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.